A Research Guide for
Facing Renal Cell Carcinoma

FDA-APPROVED The CLEAR trial established pembrolizumab + lenvatinib as one of the most active first-line combinations for advanced clear cell RCC, with an objective response rate of 71% and a complete response rate of approximately 16%. The combination improved progression-free survival and overall survival across all IMDC risk groups.

FDA-APPROVED CheckMate 9ER demonstrated that nivolumab + cabozantinib improved progression-free survival, overall survival, and objective response rate compared to sunitinib in first-line advanced RCC. The combination offered a favorable balance of efficacy and tolerability, with a 40% response rate.

FDA-APPROVED JAVELIN Renal 101 (NCT02684006) led to FDA approval of avelumab + axitinib for first-line advanced RCC in 2019, with an objective response rate of about 51% and improved progression-free survival versus sunitinib. Unlike the other first-line IO+TKI combinations, however, it has not shown a clear overall-survival benefit, so it is used less often than pembrolizumab- or nivolumab-based combinations.

FDA-APPROVED KEYNOTE-564 was the first trial to show an overall survival benefit for adjuvant therapy in RCC. One year of pembrolizumab after nephrectomy in patients with intermediate-high, high-risk, or M1 NED (no evidence of disease after metastasectomy) clear cell RCC improved disease-free survival and, with longer follow-up, overall survival. This changed the paradigm for high-risk localized RCC.

FDA-APPROVED Belzutifan is a first-in-class HIF-2α inhibitor. Initially approved in 2021 for VHL disease-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors, it received a broader FDA approval on December 14, 2023 for advanced RCC in patients previously treated with a PD-1/PD-L1 inhibitor and a VEGF-TKI, based on the LITESPARK-005 trial (NCT04195750). LITESPARK-005 showed an objective response rate of 22% versus 3.5% with everolimus, with improved progression-free survival. It targets the HIF pathway that is dysregulated in essentially all clear cell RCC. Belzutifan combinations have since advanced: belzutifan + lenvatinib improved progression-free survival after prior immunotherapy (LITESPARK-011), and belzutifan + pembrolizumab is now FDA-approved as adjuvant therapy after surgery (LITESPARK-022, June 2026). A first-line triplet adding belzutifan (LITESPARK-012) did not meet its goals.

FDA-APPROVED CheckMate 214 established the nivolumab + ipilimumab (IO+IO) combination as a first-line option for intermediate and poor-risk advanced RCC. This dual checkpoint blockade approach produces durable complete responses in approximately 10–12% of patients — some lasting beyond 5 years. However, it is associated with higher rates of immune-related adverse events than IO+TKI combinations.

• CT scan with contrast (CT abdomen/pelvis): The primary diagnostic tool. A renal mass that enhances with contrast (takes up the dye) is considered suspicious for RCC. CT also evaluates the renal vein and inferior vena cava (IVC) for tumor thrombus, lymph nodes, and distant metastases.
• MRI: Used when CT contrast is contraindicated (allergy, kidney function concerns), or to better evaluate tumor thrombus extending into the IVC. MRI is also helpful for characterizing indeterminate renal masses.
• Chest CT: Standard for staging to evaluate for lung metastases, the most common site of RCC spread.
• Bone scan and brain MRI: Not routinely performed unless there are specific symptoms or advanced-stage disease.
• Ultrasound: Often the initial study that detects an incidental renal mass, but CT or MRI is required for full characterization.

Biopsy of a renal mass is not routinely required before surgery for clearly suspicious masses, because imaging is highly accurate for RCC. However, biopsy is recommended in several situations:

• Before active surveillance: To confirm malignancy and determine histologic subtype
• Before ablation (cryoablation, radiofrequency ablation): To establish diagnosis before a treatment that does not provide a surgical specimen
• Metastatic disease before systemic therapy: To confirm histology (clear cell vs. non-clear cell) which directly affects treatment choice
• Indeterminate renal masses: When imaging cannot distinguish RCC from oncocytoma, angiomyolipoma, or other benign lesions
• Suspected lymphoma or metastasis from another cancer: When the kidney mass may not be primary RCC

Modern image-guided percutaneous biopsy has a diagnostic accuracy of approximately 90–95% with a very low complication rate. The historical concern about needle track seeding is essentially unfounded with current core needle techniques.

• Complete blood count (CBC): May show anemia (common in advanced RCC) or polycythemia (rare, from tumor-produced erythropoietin)
• Comprehensive metabolic panel: Kidney function (creatinine, GFR), liver function, calcium (hypercalcemia occurs in ~10–15% of advanced RCC)
• Lactate dehydrogenase (LDH): Elevated in some advanced cases; used in prognostic risk models
• Urinalysis: May show microscopic hematuria
• Corrected calcium: Hypercalcemia is an adverse prognostic factor (IMDC criteria)

The IMDC (also called Heng) criteria are the standard prognostic model for metastatic RCC. Six factors are assessed:

1. Less than 1 year from diagnosis to start of systemic therapy
2. Karnofsky performance status <80%
3. Hemoglobin below lower limit of normal
4. Corrected calcium above upper limit of normal
5. Neutrophil count above upper limit of normal
6. Platelet count above upper limit of normal

• Favorable risk (0 factors): ~43 months median OS. Best outcomes. Debate about IO+TKI vs. IO+IO vs. TKI monotherapy.
• Intermediate risk (1–2 factors): ~22 months median OS. IO+TKI or IO+IO standard.
• Poor risk (3–6 factors): ~8 months median OS historically, improving with IO combinations. IO+TKI or IO+IO essential.

• What is my tumor stage and grade?
• Is the tumor clear cell or a different histologic subtype?
• Is there tumor thrombus in the renal vein or IVC?
• What is my IMDC risk category (if metastatic)?
• Could this be a hereditary kidney cancer? Should I be tested for VHL or other syndromes?
• Are there signs of metastases on my staging scans?
• Am I a candidate for partial nephrectomy (kidney-sparing surgery)?
• Is a biopsy needed before we decide on treatment?

For metastatic RCC, doctors use a tool called the IMDC (International Metastatic RCC Database Consortium) score to estimate how a cancer is likely to behave. It assigns one point for each of six factors that tend to be associated with more aggressive disease: poor performance status, being diagnosed and starting treatment within a year, anemia (low hemoglobin), high calcium, high neutrophils, and high platelets.

• 0 factors — Favorable risk: Statistically, the best outcomes. Modern IO+TKI combinations achieve 3-year survival rates above 60% in favorable-risk patients in recent trials.
• 1–2 factors — Intermediate risk: The most common category (about 35% of patients). IO+TKI combinations have substantially improved outcomes over older treatments in this group.
• 3–6 factors — Poor risk: Associated with faster-growing disease and historically poorer outcomes, but IO+IO (nivolumab + ipilimumab) has produced complete responses lasting 5+ years in 10–12% of patients in this group.

RCC staging follows the TNM (Tumor, Nodes, Metastasis) system. Here is what each stage means in practical terms:

• Stage I: Tumor ≤7 cm, confined entirely to the kidney. No spread to lymph nodes or distant organs. Surgery (partial or radical nephrectomy) is curative in most cases. 5-year survival above 90%. Adjuvant therapy not routinely recommended unless high-risk features on final pathology.
• Stage II: Tumor >7 cm, still confined to the kidney. Still treated surgically with curative intent. Higher risk of recurrence than Stage I. Adjuvant immunotherapy (pembrolizumab or belzutifan + pembrolizumab) should be discussed with your oncologist based on final pathology.
• Stage III: Tumor extends into major veins (renal vein or IVC) or invades beyond the kidney but within Gerota's fascia, and/or involves regional lymph nodes. Surgery remains possible and is performed with curative intent at experienced centers. IVC thrombus (tumor clot in the large vein leading to the heart) requires specialized surgical expertise. High recurrence risk — adjuvant immunotherapy is generally recommended.
• Stage IV: Spread beyond Gerota's fascia or to distant organs (lungs, liver, bones, brain). This is metastatic disease. Treatment focuses on controlling the cancer with systemic therapy (IO+TKI or IO+IO combinations) and, in selected patients, surgery. Cure is not the typical goal at Stage IV, but long-term disease control and even complete remission are achievable with modern treatments — some patients have remained off all therapy for 5+ years after achieving a complete response.

The most common subtype. Driven by loss of the VHL tumor suppressor gene in the vast majority of cases, leading to overactivation of the HIF pathway and increased VEGF (vascular endothelial growth factor) signaling. This is why anti-VEGF therapies (TKIs) are so effective in clear cell RCC. Also responds well to immunotherapy. All major first-line IO+TKI trials enrolled predominantly clear cell patients.

The second most common subtype. Two types: Type 1 (MET-driven, generally better prognosis) and Type 2 (heterogeneous, often worse prognosis, may be FH-driven). Papillary RCC responds less well to traditional VEGF-TKIs and immunotherapy than clear cell RCC. MET inhibitors (savolitinib, cabozantinib) are being studied specifically for this subtype.

Generally the most indolent (slow-growing) RCC subtype with the best prognosis overall. Rarely metastasizes. When localized, surgery is usually curative. When advanced (rare), limited response to standard RCC therapies. Associated with Birt-Hogg-Dubé syndrome when combined with oncocytomas.

Rare and aggressive subtypes. Renal medullary carcinoma is almost exclusively found in individuals with sickle cell trait and carries a very poor prognosis. Collecting duct carcinoma is also aggressive. Both are typically treated with platinum-based chemotherapy rather than standard RCC immunotherapy-TKI regimens. Clinical trials are essential.

Your specific subtype affects both what treatments your oncologist will recommend and whether clinical trials are especially important for you.

• Clear cell RCC: The most studied and best-treated subtype. All major IO+TKI and IO+IO clinical trials were conducted primarily in clear cell RCC. Belzutifan (which targets the HIF-2α pathway — the root driver of clear cell RCC) is specifically FDA-approved for this subtype. This guide is primarily about clear cell RCC.
• Papillary RCC (Type 1 — MET-driven): May respond to cabozantinib (which blocks MET receptors) or, if MET status is confirmed, to selective MET inhibitors like savolitinib. Ask your oncologist whether your tumor has been tested for MET alterations.
• Papillary RCC (Type 2 or HLRCC-associated): More aggressive. A specialized combination (bevacizumab + erlotinib) has shown remarkable results in FH-mutation associated papillary RCC. Genetic testing for FH mutations is essential in young patients with Type 2 papillary RCC.
• Chromophobe RCC: Generally slow-growing. If metastatic, there is no well-established standard therapy — clinical trials and referral to an expert center are strongly recommended.
• Collecting duct or medullary RCC: Rare and aggressive. Platinum-based chemotherapy is typically first-line. If you have sickle cell trait, this diagnosis should prompt immediate genetic counseling for family members.

About 3–5% of RCC cases are caused by inherited gene mutations. You may be at higher risk for a hereditary kidney cancer syndrome if:

• You were diagnosed with RCC under age 46
• You have tumors in both kidneys, or multiple tumors in one kidney
• A parent, sibling, or child has been diagnosed with RCC
• You have other findings associated with known syndromes: cysts in the pancreas or cerebellum, benign tumors of the lung or skin, or a history of pheochromocytoma

If any of these apply, ask your oncologist about a referral to a genetic counselor. The main hereditary kidney cancer syndromes are: VHL syndrome (clear cell RCC, eye/brain tumors, pheochromocytoma); Hereditary papillary RCC (MET); HLRCC (FH mutation) (aggressive papillary RCC + skin/uterine leiomyomas); Birt-Hogg-Dubé (FLCN) (chromophobe + lung cysts + skin bumps). Knowing your genetic status matters: it may change your treatment (belzutifan is specifically approved for VHL-syndrome-associated RCC), change how frequently family members need to be screened, and affect clinical trial eligibility.

Partial nephrectomy removes the tumor while preserving the remaining normal kidney tissue. It is the preferred surgery for tumors ≤7 cm (T1a and T1b) whenever technically feasible. Benefits include:

• Equivalent cancer control compared to radical nephrectomy for appropriately selected tumors
• Better long-term kidney function preservation — reducing risk of chronic kidney disease and cardiovascular events
• Can be performed robotically (most common approach now), laparoscopically, or open
• Complication rates are acceptable at experienced centers (approximately 5–10% risk of urinary leak, bleeding)

Key point: If your surgeon recommends removing the entire kidney for a tumor <7 cm, ask why a partial nephrectomy is not possible. Get a second opinion at a high-volume center if needed.

Radical nephrectomy removes the entire kidney, surrounding fat, and sometimes the adrenal gland. It is appropriate for:

• Large tumors (>7 cm) where partial nephrectomy is not feasible
• Centrally located tumors with complex anatomy
• Tumors with renal vein or IVC thrombus (may require IVC thrombectomy with cardiac surgery team)
• Most patients have sufficient kidney function in the remaining kidney to live normally

Historically, removing the primary kidney tumor even when metastases were present was standard practice, based on older trials (SWOG 8949, EORTC 30947) conducted in the interferon era. However, the CARMENA trial (France, sunitinib era) showed that:

• Intermediate and poor-risk patients: Sunitinib alone was non-inferior to nephrectomy followed by sunitinib. Many patients did not benefit from surgery.
• The role of cytoreductive nephrectomy in the IO+TKI era remains debated. NCCN guidelines recommend it selectively — primarily for patients with favorable risk and limited metastatic burden where the primary tumor represents the majority of disease.
• Immediate systemic therapy (IO+TKI) is now preferred for most patients with metastatic RCC, with deferred nephrectomy considered only in patients who respond well to initial treatment.

• Can I have a partial nephrectomy instead of removing the whole kidney?
• How many kidney surgeries does your center perform each year?
• Will the surgery be robotic, laparoscopic, or open?
• What is the expected recovery time?
• What is my kidney function now, and what will it be after surgery?
• Is there tumor thrombus that requires additional surgical planning?
• Based on the final pathology, will I need any additional treatment?

Active surveillance works best for patients where the risks of surgery outweigh the risks of the tumor growing. Good candidates typically include:

• Older adults (>70) where surgery carries meaningful cardiac, anesthetic, or recovery risks, and the tumor is unlikely to cause problems within their expected lifespan
• Patients with multiple medical problems (heart disease, advanced diabetes, lung disease) for whom any surgical procedure carries elevated risk
• Patients with a single kidney or already-impaired kidney function where removing any kidney tissue would likely push them into dialysis
• Small tumors (<2 cm) that are growing extremely slowly or not at all on serial imaging
• Patients who have already received a confirmed benign diagnosis on biopsy (for example, an oncocytoma — a non-cancerous kidney tumor that looks like RCC on imaging)

Active surveillance requires commitment: you must keep every scheduled imaging appointment and report new symptoms promptly. The success of this approach depends entirely on catching any significant change early. If you miss multiple follow-up appointments, your oncology team may recommend revisiting whether surveillance remains the right choice.

FDA-APPROVED KEYNOTE-564 randomized 994 patients with high-risk clear cell RCC after nephrectomy to one year of pembrolizumab (200 mg IV every 3 weeks, 17 doses) versus placebo.

• Eligible patients: Intermediate-high risk (pT2 grade 4 or sarcomatoid, pT3, pT4), high risk (any pathologic stage with regional lymph node involvement), or M1 NED (metastatic disease rendered to no evidence of disease by surgery)
• Disease-free survival: Hazard ratio 0.68 (32% reduction in recurrence risk) at 30-month follow-up
• Overall survival: Hazard ratio 0.62 at extended follow-up (38% reduction in death risk) — statistically significant
• Side effects: Immune-related adverse events in ~32% (thyroid disorders most common, also adrenal insufficiency, hepatitis, colitis, pneumonitis). Most manageable but some are permanent (thyroid dysfunction).

Key consideration: The OS benefit was demonstrated in a population enriched for high-risk features. Not all patients with localized RCC benefit. The decision to pursue adjuvant therapy should consider individual risk, patient preferences, and willingness to accept potential immune-related side effects.

FDA-APPROVED JUNE 2026 On June 12, 2026, the FDA approved a second option for after-surgery treatment: belzutifan (Welireg), a HIF-2α inhibitor pill, combined with pembrolizumab, for high-risk clear cell RCC after the kidney (and any removable metastases) have been taken out.

• What the trial showed: In LITESPARK-022, adding belzutifan to pembrolizumab lowered the risk of the cancer coming back compared with pembrolizumab alone. At two years, 80.7% of people on the combination were cancer-free versus 73.7% on pembrolizumab alone. It is too early to know whether people live longer (overall-survival data are not yet mature).
• How it is taken: Belzutifan is one tablet daily; pembrolizumab is an IV (or under-the-skin) infusion, for up to about a year.
• Side effects: The combination causes more side effects than pembrolizumab alone — most notably anemia (low red blood cells) and low blood-oxygen levels (hypoxia), which your team will monitor with blood counts and an oxygen-level check. Belzutifan can harm a pregnancy and can make hormonal birth control less effective.
• Choosing: The extra benefit comes with more side effects, so this is a shared decision with your oncologist.

• Based on the final pathology, what is my risk of recurrence?
• Am I a candidate for adjuvant pembrolizumab — or for the newer belzutifan + pembrolizumab combination?
• What are the potential side effects of one year of immunotherapy?
• If I do not take adjuvant therapy, what is my surveillance schedule?
• How often should I have imaging follow-up?
• Should I be tested for hereditary kidney cancer syndromes?

FDA-APPROVED (NCT02811861)

• ORR: 71% (CR 16%)
• Median PFS: 23.9 months vs. 9.2 months (sunitinib)
• OS: Significant improvement (HR 0.66)
• Dosing: Pembrolizumab 200 mg IV q3w + lenvatinib 20 mg PO daily (frequent dose reductions of lenvatinib needed — ~67% of patients required at least one dose reduction)
• Key toxicities: Hypertension, diarrhea, hypothyroidism, fatigue, proteinuria, palmar-plantar erythrodysesthesia. Lenvatinib dose reductions are common and expected.

FDA-APPROVED (NCT03141177)

• ORR: 55.7% (CR 8%)
• Median PFS: 16.6 months vs. 8.3 months (sunitinib)
• OS: Significant improvement (HR 0.70 at extended follow-up)
• Dosing: Nivolumab 240 mg IV q2w + cabozantinib 40 mg PO daily (reduced from standard cabozantinib dose of 60 mg)
• Key toxicities: Diarrhea, hypertension, hand-foot syndrome, fatigue, hepatotoxicity. Generally considered to have a manageable tolerability profile.

FDA-APPROVED (NCT02853331)

• ORR: 60% (CR 9%)
• Median PFS: 15.4 months vs. 11.1 months (sunitinib)
• OS: Significant improvement (HR 0.73)
• Dosing: Pembrolizumab 200 mg IV q3w + axitinib 5 mg PO BID (dose titration up to 10 mg BID if tolerated)
• Key toxicities: Hepatotoxicity (requires close LFT monitoring, especially in the first 3 months), hypertension, diarrhea, hypothyroidism

FDA-APPROVED (NCT02231749)

• For intermediate/poor-risk patients: ORR 42%, CR 10–12%. Median OS not reached at initial analysis; 5-year OS 43%.
• For favorable-risk patients: Less clear benefit — ORR lower than sunitinib, with longer time to response. NCCN lists IO+TKI as preferred for favorable-risk.
• Dosing: Nivolumab 3 mg/kg + ipilimumab 1 mg/kg IV q3w × 4 doses, then nivolumab 480 mg IV q4w maintenance
• Key advantage: Durable complete responses in ~10–12% of intermediate/poor-risk patients; some patients have been off all therapy for 5+ years in sustained CR.
• Key toxicities: Higher rate of grade 3–4 immune-related adverse events (~46%) compared to IO+TKI combinations. Includes hepatitis, colitis, pneumonitis, adrenal insufficiency, hypophysitis. About 22% discontinue due to toxicity.

• What is my IMDC risk category and how does it affect treatment choice?
• Which IO+TKI or IO+IO combination do you recommend for me and why?
• What are the expected side effects and how will they be managed?
• How often will I need imaging to check response?
• If I have a good response, could treatment be stopped at some point?
• Should I have a biopsy to confirm my cancer is clear cell before starting?
• Is there a clinical trial that might be better for my situation?
• What happens if my cancer progresses on the first treatment?

• Cabozantinib: A multi-kinase TKI targeting VEGFR, MET, and AXL. METEOR trial showed improved PFS and OS compared to everolimus in TKI-pretreated patients. Dose: 60 mg PO daily.
• Lenvatinib + everolimus: Combination of a VEGF-TKI and mTOR inhibitor. Study 205 showed improved PFS compared to everolimus alone. Dose: lenvatinib 18 mg + everolimus 5 mg daily.
• Tivozanib (Fotivda): A highly selective VEGFR-TKI. TIVO-3 trial showed improved PFS in the third/fourth-line setting. Dose: 1.34 mg PO daily, 3 weeks on/1 week off.
• Axitinib: A potent VEGFR-TKI for second-line. Dose: 5 mg PO BID, with dose escalation possible.
• Everolimus: An mTOR inhibitor. Used when TKI options are exhausted. Dose: 10 mg PO daily.
• Nivolumab monotherapy: If not previously exposed to IO. CheckMate 025 showed OS benefit over everolimus in TKI-pretreated patients.

FDA-APPROVED Belzutifan (Welireg) is the first HIF-2α inhibitor approved by the FDA. Initially approved for VHL disease-associated RCC, CNS hemangioblastomas, and pancreatic NETs (2021), the FDA granted a broader approval on December 14, 2023 for advanced clear cell RCC in patients previously treated with a PD-1/PD-L1 inhibitor and a VEGF-TKI, based on LITESPARK-005 (NCT04195750). Key results: ORR 22% versus 3.5% with everolimus, with improved progression-free survival.

• Dosing: 120 mg PO daily
• Key toxicity: Anemia (very common — expected pharmacologic effect of HIF-2α inhibition on erythropoietin), hypoxia. Monitor hemoglobin closely.

For most patients with metastatic RCC, first-line IO+TKI therapy works well for a period of time — often 12–24 months or longer. Eventually, most cancers find ways to grow again. This is called progression. Here is what to expect when that happens:

• This is expected, not a failure. The goal of first-line therapy was to control the cancer for as long as possible and preserve your quality of life. Progression after a good run on first-line therapy does not mean your oncologist made the wrong choice or that you did anything wrong.
• You will not run out of options. Second-line treatments are available and active. The RCC treatment landscape now includes cabozantinib, lenvatinib+everolimus, tivozanib, belzutifan (Welireg), nivolumab, and clinical trials with new agents. Each works through a different mechanism, so prior resistance to IO+TKI does not predict resistance to these drugs.
• Re-biopsy may sometimes be recommended to understand whether the tumor has changed histologically (for example, developed sarcomatoid features) or acquired resistance mechanisms. Ask your oncologist whether a repeat biopsy would change management in your situation.
• Clinical trial enrollment is especially worth exploring at progression. Several trials specifically target IO-refractory RCC with novel mechanisms (casdatifan, next-gen HIF-2α inhibitors, CD70-directed therapies) that are only available in the trial setting.

Belzutifan (Welireg) is a once-daily pill that works through a completely different mechanism from the IO and TKI drugs used in first-line therapy. Instead of blocking blood vessel growth or releasing the brakes on your immune system, it shuts off a key protein (HIF-2α) that tells the cancer cell to keep growing. Because the mechanism is different, it can work even when prior IO+TKI therapy has stopped being effective.

The LITESPARK-005 trial showed that belzutifan kept the cancer from growing for longer than everolimus (the previous standard second-line option) in patients who had already received IO and VEGF-TKI therapy. Belzutifan is FDA-approved for this indication as of December 2023.

What to know if you are offered belzutifan second-line:

• It is taken as a tablet once daily at the same time each day, with or without food.
• Your blood counts (especially hemoglobin) will be checked before each dose because belzutifan predictably lowers red blood cell counts in most patients. Fatigue and shortness of breath may worsen as a result.
• Your oxygen levels will be monitored because belzutifan can lower blood oxygen in some patients.
• If you take hormonal birth control, you must switch to a non-hormonal method (belzutifan makes hormonal contraceptives less effective).
• A newer combination, belzutifan + lenvatinib (LITESPARK-011), has shown even better results than cabozantinib in clinical trials and is expected to be FDA-approved in 2026. Ask your oncologist if this combination is available.

• What is causing my cancer to progress now — resistance to the IO, the TKI, or both?
• What second-line options do you recommend for me, and why that one over the others?
• Is belzutifan (Welireg) an option for me? What about the belzutifan + lenvatinib combination?
• Should we get a new biopsy to see if my cancer has changed?
• Are there clinical trials for patients in my situation?
• Do I need to change my surveillance imaging schedule now?
• Should I be seen at a larger academic center or specialized kidney cancer program at this point?

Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) work by releasing the brakes on your immune system. Sometimes this causes the immune system to attack normal tissues. These "immune-related" side effects can appear at any time — even months after treatment starts.

Call your oncology team immediately or go to an ER for any of these:

• New or worsening shortness of breath: May indicate immune pneumonitis. Do not wait — this can progress rapidly.
• Severe diarrhea (≥4 bowel movements above baseline per day) or bloody stool: May indicate immune colitis. Loperamide alone is not enough — call first.
• Yellow skin or eyes (jaundice), or dark urine: May indicate immune hepatitis. Requires urgent blood tests.
• New severe headache, visual changes, confusion, or weakness: May indicate rare but serious immune-mediated neurologic effects including hypophysitis.
• Chest pain, irregular heartbeat, or severe fatigue with exertion: Rare but serious: immune myocarditis. This is a medical emergency.
• Severe skin reaction with blistering or peeling: Immune dermatitis requiring immediate evaluation.

Manageable (can wait until next appointment if not severe): Mild rash, mild fatigue, thyroid symptoms (weight changes, feeling hot/cold), joint aches.

Tyrosine kinase inhibitors (cabozantinib, lenvatinib, axitinib) are taken daily by mouth. Their side effects are predictable and dose-related — meaning they often improve with a dose reduction. Do not stop your TKI on your own; call your oncologist first.

• High blood pressure (hypertension): Monitor your blood pressure at home twice daily, especially in the first month. Keep a log. Target is below 140/90. If readings consistently exceed 160/100, call your team — blood pressure medication may need to be started or adjusted. Uncontrolled high blood pressure can lead to stroke or heart attack.
• Hand-foot syndrome (palmar-plantar erythrodysesthesia): Redness, swelling, tingling, and blistering on palms and soles. Prevent by: moisturizing hands and feet twice daily starting day 1, wearing padded socks and comfortable shoes, avoiding pressure and friction. At the first sign of redness or tingling, tell your team — early treatment prevents progression to painful blistering.
• Diarrhea: Very common. Loperamide (Imodium) 2 mg after the first loose stool, then 2 mg every 2 hours is first-line for grade 1–2. Avoid high-fiber foods, raw vegetables, and dairy. Stay very well hydrated. Call your team if you have ≥4 loose stools per day or diarrhea lasting >2 days despite loperamide.
• Fatigue: Among the most common and impactful side effects. Rule out treatable causes (hypothyroidism, anemia) with your team. Short daily walks — even 10 minutes — can improve cancer-related fatigue. Prioritize sleep hygiene. Energy conservation techniques (pacing activities, sitting rather than standing) help.
• Nausea: Take your TKI with food (except cabozantinib, which should be taken on an empty stomach). Ginger tea, small frequent meals, and over-the-counter antinausea medicines may help. Prescription antiemetics are available if needed.

Belzutifan (Welireg) is a pill you take once a day. Unlike TKIs or immunotherapy, it works by blocking a specific protein called HIF-2α that drives tumor growth when your VHL gene is not working properly (which is the case in most clear cell kidney cancers).

The two side effects unique to belzutifan:

• Anemia (low red blood cells): Belzutifan reduces a hormone (EPO) that tells your body to make red blood cells. Most patients notice this as increased fatigue and sometimes shortness of breath. Your team will check your blood counts before each dose and may hold the medication if counts are too low. In some cases, blood transfusions or EPO-stimulating medications are used. Tell your team right away about worsening tiredness or shortness of breath.
• Low blood oxygen (hypoxia): Belzutifan can reduce oxygen levels in your blood. Your team will periodically check your oxygen saturation with a fingertip probe. If you notice shortness of breath at rest or waking at night feeling breathless, call your team immediately. This is a reason to temporarily hold the medication while the cause is investigated.

Birth control interaction: Belzutifan makes hormonal birth control pills and patches less effective. If you use hormonal contraception, you must use a non-hormonal method (condoms, IUD, etc.) while taking belzutifan and for at least 1 week after stopping it. Discuss pregnancy prevention with your doctor before starting.

• What phone number should I call after hours or on weekends if I develop a serious side effect?
• Which symptoms should send me to the emergency room vs. calling the office?
• What over-the-counter medications are safe to take for nausea, diarrhea, and pain while on my treatment?
• What is the plan if a side effect requires me to hold my medication?
• Is there a financial counselor or social worker on the team I can speak with about managing the cost of my treatment?
• Will I need to avoid grapefruit, supplements, or specific medications while on TKI therapy?

• IO+TKI vs. IO+IO debate: In Europe and Canada, all four first-line options (3 IO+TKI, 1 IO+IO) are available. The choice often depends on local reimbursement, physician preference, and patient factors.
• Sunitinib remains standard in many LMIC: Where IO combinations are not accessible or affordable, sunitinib or pazopanib monotherapy remain the first-line standard. Tivozanib and cabozantinib monotherapy are alternatives.
• Belzutifan: FDA-approved for VHL-associated RCC (2021), advanced ccRCC after PD-1/PD-L1 + VEGF-TKI (December 2023), and — in combination with pembrolizumab — adjuvant high-risk ccRCC (June 2026). In Europe, the European Commission granted conditional approval in February 2025 for VHL-associated tumors and for advanced ccRCC after at least two prior lines (including a PD-1/PD-L1 inhibitor and VEGF therapies); belzutifan is also approved in Japan. In Australia, belzutifan is not yet TGA-approved for advanced RCC (under evaluation). The adjuvant belzutifan + pembrolizumab combination is, so far, FDA-approved only (not yet approved by the EMA, Japan's PMDA, Health Canada, the UK's MHRA, or Australia's TGA).
• Active surveillance for small renal masses: Expanding globally. AUA, EAU, and other international guidelines now support surveillance for select cT1a masses.
• Cytoreductive nephrectomy debate: The CARMENA trial (conducted primarily in France) changed practice globally, reducing the rate of upfront nephrectomy in metastatic RCC.

Every major RCC drug manufacturer has a patient assistance program. These programs provide free medication to eligible uninsured/underinsured patients, and copay cards to reduce out-of-pocket costs for insured patients.

• Pembrolizumab (Keytruda) — Merck Keytruda Helps: 1-855-257-3932 • keytruda.com/helping
• Nivolumab/Ipilimumab (Opdivo/Yervoy) — BMS Access Support: 1-800-721-5072 • bms.com/patient-assistance
• Belzutifan (Welireg) — Welireg Compass Program: 1-855-572-9444 • welireg.com/compass
• Cabozantinib (Cabometyx) — Exelixis Access Services: 1-844-394-6567 • cabometyx.com/access
• Lenvatinib (Lenvima) — Eisai Assist: 1-888-274-2378 • eisai-inc.com
• Axitinib (Inlyta) — Pfizer RxPathways: 1-888-RX-PATHWAYS • rxpathways.com
• Sunitinib (Sutent) — Pfizer RxPathways: same as above

Each program has different income and insurance eligibility criteria. Ask your oncology clinic's financial counselor or nurse navigator to help you apply — many clinics keep updated application materials.

Non-profit foundations offer grants to help cover copays, deductibles, and other costs. Funds open and close frequently — apply as early as possible.

• PAN Foundation (Patient Access Network): Grants for copays and cost-sharing. 1-866-316-7263 • panfoundation.org
• HealthWell Foundation: Income-based copay assistance (<400% federal poverty level). 1-800-675-8416 • healthwellfoundation.org
• CancerCare: Financial assistance grants, financial counseling, and case management. 1-800-813-4673 • cancercare.org
• Kidney Cancer Association: Resource navigation and limited financial assistance. 1-800-850-9132 • kidneycancer.org
• NORD (National Organization for Rare Disorders): Assistance for hereditary RCC syndromes. rarediseases.org

• Prior authorization: Most RCC drugs require prior authorization. Your oncology office will submit this, but delays are common. Ask your nurse navigator to call and follow up on pending authorizations, especially before your first infusion or new oral agent prescription.
• Step therapy requirements: Some insurers require you to try a lower-cost drug first before approving the recommended one. Your oncologist can often submit a "step therapy exception" — do not accept a denial without requesting an exception.
• Appeals: Denied claims can and should be appealed. Ask for the denial in writing with specific reason codes. Your oncologist's office can submit a peer-to-peer review. Free appeals assistance is available through the Patient Advocate Foundation (patientadvocate.org) and State Insurance Commissioner offices.
• Medicare Extra Help / Low Income Subsidy: If you have Medicare Part D, you may qualify for Extra Help to reduce drug copays to under $10/month. Apply at ssa.gov or call 1-800-772-1213.
• Utah-specific: The Utah Medicaid program, 340B-participating clinics (University of Utah, Intermountain), and the Utah Cancer Action Network can provide additional resource guidance. Contact HCI Patient Financial Services at (801) 585-0303.

DE-ADOPTED HD IL-2 was the first immunotherapy for RCC (FDA approved 1992). It produced durable complete responses in approximately 5–7% of patients. However, it required ICU-level care due to severe toxicity (capillary leak syndrome, hypotension, organ dysfunction), and the vast majority of patients did not benefit. With the advent of IO+TKI combinations that achieve higher response rates with substantially better tolerability, HD IL-2 is now rarely used. Some centers still consider it for highly selected, very fit patients.

FAILED Multiple large randomized trials tested TKIs after nephrectomy for high-risk localized RCC:

• S-TRAC (sunitinib): Showed DFS improvement but no OS benefit. FDA-approved but not widely adopted due to toxicity without proven survival benefit.
• ASSURE (sunitinib/sorafenib): No DFS or OS benefit. Negative trial.
• PROTECT (pazopanib): Primary endpoint not met.
• ATLAS (axitinib): No DFS benefit in the overall population.

These failures make the KEYNOTE-564 pembrolizumab result even more significant — it is the only adjuvant therapy with proven OS benefit in RCC.

DE-ADOPTED Interferon-alpha was a standard first-line treatment for metastatic RCC before targeted therapies. Response rates were approximately 10–15% with significant flu-like side effects. It has been completely replaced by TKIs and IO combinations. No role in current RCC management except as historical comparator.

SUPERSEDED IMmotion151 showed PFS benefit for atezolizumab + bevacizumab vs. sunitinib in PD-L1-positive patients, but did not demonstrate overall survival benefit. With multiple IO+TKI combinations showing OS benefit, this regimen has been largely superseded and is not among NCCN-preferred first-line options.

FAILED CONTACT-03 tested whether adding an IO (atezolizumab) to cabozantinib after prior IO+TKI progression would be better than cabozantinib alone. The trial was negative — no PFS or OS benefit from adding atezolizumab. This suggests that re-challenging with IO after IO progression may not be effective, though the question is not fully settled.

• Before treatment: Your team will check whether you might be pregnant if you are of childbearing potential.
• Birth control: Effective contraception is advised during treatment and for a period afterward (how long depends on the specific drug). Importantly, belzutifan can make hormonal birth control (the pill, patch, etc.) less reliable, so an additional or non-hormonal method is recommended.
• If cancer is found during pregnancy: Localized kidney cancer can sometimes be treated with surgery, with timing chosen to be as safe as possible — managed together with a maternal-fetal medicine (high-risk pregnancy) specialist.
• Breastfeeding: These medicines are generally not compatible with breastfeeding; discuss alternatives with your team.
• Fertility: If you hope to have children later, ask about fertility preservation before starting treatment.

• Could any of my treatments affect a current or future pregnancy?
• What kind of birth control should I use during treatment, and for how long after?
• If I want children in the future, what are my fertility-preservation options?
• Should I be tested for a hereditary kidney-cancer syndrome that could affect my family?

• Recovery from partial or radical nephrectomy typically takes 2–6 weeks. Plan for help with driving, lifting, and household tasks.
• Robotic surgery generally has a shorter recovery (1–3 weeks) than open surgery (4–6 weeks).
• Watch for post-surgical complications: Fever, increasing pain, drainage from incision, blood in urine beyond the first few days. Contact the surgeon promptly.
• Follow-up imaging is critical. Help keep track of the surveillance schedule.

• Blood pressure monitoring: TKIs commonly cause hypertension. Home blood pressure monitoring (1–2 times daily) and maintaining a log for the oncologist is very helpful.
• Skin and hand-foot changes: TKIs can cause hand-foot syndrome (peeling, blistering on palms and soles). Moisturizing, comfortable shoes, and early reporting are important.
• Thyroid function: IO can cause thyroid problems. Symptoms include fatigue, weight changes, feeling cold or overheated. Routine blood tests monitor this.
• Immune-related side effects: Be alert for sudden onset diarrhea, rash, shortness of breath, unusual fatigue, or jaundice (yellowing of skin/eyes). These may indicate immune-mediated side effects that require prompt treatment with steroids.
• Emotional support: Living with ongoing cancer treatment is psychologically demanding. The Kidney Cancer Association (1-800-850-9132) offers peer support programs and educational resources.

There is no single "kidney cancer diet." However, several evidence-based principles apply:

• Protein intake: Adequate protein (1.0–1.5 g/kg body weight/day) is important to preserve muscle mass during treatment, especially if you are experiencing fatigue, decreased appetite, or are on TKI therapy. Good sources include lean meat, poultry, fish, eggs, dairy, legumes, and tofu.
• Stay hydrated: TKI therapy can worsen kidney function, and adequate hydration (6–8 cups of water daily, more in heat) is protective. Your team may monitor serum creatinine periodically.
• Grapefruit and grapefruit juice: Avoid entirely while on TKIs. Grapefruit inhibits CYP3A4, the enzyme that breaks down most TKIs, leading to dangerously high drug levels and increased toxicity.
• St. John's Wort and herbal supplements: Many herbal supplements interact with RCC drugs. St. John's Wort (a CYP3A4 inducer) substantially reduces blood levels of TKIs and may make them ineffective. Discuss ALL supplements with your oncologist before taking them.
• Potassium-rich foods if on ACE-inhibitors/ARBs for hypertension: Monitor potassium — these blood pressure medications can raise potassium levels, particularly if kidney function is impaired.
• Phosphorus and kidney function: If you have one kidney or have chronic kidney disease, a kidney dietitian can tailor specific nutritional guidance. Huntsman Cancer Institute and Intermountain Health both offer oncology nutrition services.

Physical activity during cancer treatment is safe and beneficial for most patients. A 2020 systematic review found that aerobic exercise and resistance training during cancer treatment are associated with improvements in fatigue, quality of life, physical function, and depression. For RCC specifically, maintaining physical fitness is relevant because fatigue is the most common side effect of both IO and TKI therapy.

• Goal: Aim for 150 minutes of moderate-intensity aerobic activity per week (walking, cycling, swimming) plus 2 days of resistance training — or whatever portion of this you can achieve consistently. Even 30 minutes of walking 3 days a week is significantly better than nothing.
• Safety considerations: Avoid high-impact activity when platelet counts are low or if you have bone metastases (fracture risk). Monitor blood pressure response to exercise. Do not exercise on days when you feel nauseated or have grade 2+ diarrhea — hydration is the priority.
• Start where you are: Many patients find their tolerance has decreased significantly at diagnosis. Begin at whatever level you can sustain, increase by 10% per week, and track your progress. Even gentle stretching and short walks have documented benefits on fatigue and mood.
• Resources: The Livestrong at the YMCA program (livestrong.org) offers free or low-cost supervised exercise programs for cancer patients at participating YMCA locations across Utah and nationally.

A kidney cancer diagnosis and the months of ongoing treatment that follow have profound psychological effects. Anxiety about disease progression, uncertainty about the future, fatigue-related mood changes, and the stress of frequent medical appointments affect the majority of patients to some degree. This is not weakness — it is a normal human response to a serious illness.

• Screening is standard: NCCN guidelines recommend distress screening at every cancer care visit. If your team has not offered you a distress thermometer or similar screening, ask about it.
• Evidence-based treatments work: Cognitive behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), and online support programs have strong evidence in cancer patients. Many oncology centers offer these through social work, psychology, or integrative medicine programs.
• Peer support: Talking with someone who has been through similar treatment is one of the most powerful sources of support. The Kidney Cancer Association (kidneycancer.org, 1-800-850-9132) offers peer mentoring and support groups. FORCE (Facing Our Risk of Cancer Empowered) has resources for hereditary RCC.
• Utah resources: Huntsman Cancer Institute offers the Huntsman at Home palliative care and social support program. The University of Utah Counseling Center and Intermountain Mental Health offer behavioral health services. LDS Family Services (for LDS community members) and Catholic Community Services offer counseling sliding-scale.

For patients with localized RCC who complete surgery and adjuvant therapy, long-term survivorship is an important and often under-addressed issue. For patients with metastatic RCC who achieve a deep, sustained response, treatment breaks and eventual treatment-free survival are now realistic goals for some.

• Surveillance schedule: After surgery for localized RCC, NCCN recommends CT of chest and abdomen/pelvis every 3–6 months for 3 years, then annually for up to 5 years (intensity varies by risk). Do not skip surveillance imaging — early detection of recurrence allows intervention before systemic spread.
• Kidney function monitoring: RCC and its treatment affect kidney function. Annual creatinine and eGFR checks are recommended indefinitely after any kidney surgery. Protect your remaining kidney function by controlling blood pressure, managing diabetes, and avoiding nephrotoxic drugs (NSAIDs, contrast-heavy imaging when alternatives exist).
• Long-term immunotherapy effects: Thyroid dysfunction from IO immunotherapy is often permanent and requires lifelong levothyroxine replacement. Adrenal insufficiency from IO is also permanent; patients must carry emergency hydrocortisone and wear a medical alert bracelet. Any surgeon, anesthesiologist, or urgent care provider must know about prior IO-related adrenal insufficiency before any procedure.
• Returning to work: Many patients with localized RCC return to work within 4–8 weeks of surgery. Patients on ongoing IO+TKI therapy often manage working while on treatment, though fatigue, scheduling demands, and side effects require accommodation. The Cancer and Careers organization (cancerandcareers.org) provides practical workplace resources.
• Questions to ask at your survivorship visit: What is my surveillance schedule and for how long? Are there late effects of my treatment I should watch for? What can I do to protect my remaining kidney function? When can I stop treatment if I remain in remission? How do I get a treatment summary and survivorship care plan?